FOx BIOSYSTEMS appoints Dr. Mark Truesdale as CEO

Sep 05, 2023 | Katleen Vandersmissen
New CEO Mark Truesdale will bring the disruptive technology of FOx Biosystems to a wider audience and ensure its further success

Diepenbeek, Belgium, September 5th, 2023

FOx BIOSYSTEMS, a dynamic company on a mission to revolutionize diagnostic development along with biopharmaceutical and life science research, announced the appointment of Dr. Mark R. Truesdale as CEO to take the company to commercial success.

Dr. Truesdale has over 20 years of experience in the life science and diagnostic sectors. He has held a variety of global leadership roles at Genetix plc, Danaher, and ThermoFisher Scientific. Most recently, he was CEO of Solentim Ltd., where he oversaw its operational and commercial scale-up which led to its acquisition by Advanced Instruments. Dr. Truesdale holds a BSc and PhD in biochemistry and molecular biology from the University of London.

Dr. Truesdale takes over from Thomas Van Elzakker, who has taken the company from a start-up to a scale-up, implementing the necessary structure to enable growth. FOx BIOSYSTEMS’ flagship product, WHITE FOx, uses an innovative fiber-optic SPR approach to characterize large biomolecules and particles and their kinetic interactions, directly in simple or complex matrices, such as whole blood or cell culture media.

Dr. Truesdale: “I am excited to join FOx BIOSYSTEMS at this stage of growth and am looking forward to using my skills to bring the company to commercial success. WHITE FOx has enormous potential in a range of life science applications, and I‘m confident it will make a very real difference to the field.”

“We are very happy to have Mark in this position. He is the ideal leader to bring this disruptive technology to a wider audience and ensure its further success.” - Katleen Vandersmissen, President of FOx BIOSYSTEMS’ Board of Directors

About FOx BIOSYSTEMS:

FOx BIOSYSTEMS is a Belgian company with a mission to revolutionize the life sciences and pharmacological research market with innovative real-time, label-free analysis products. The basis of their success is a novel fiber-optic-based SPR biosensor which enables users to generate high-quality, cost-effective biomolecular data fast, and over a wide range of applications.

For more information visit: www.foxbiosystems.com.

Diepenbeek, Belgium, September 5th, 2023

FOx BIOSYSTEMS, a dynamic company on a mission to revolutionize diagnostic development along with biopharmaceutical and life science research, announced the appointment of Dr. Mark R. Truesdale as CEO to take the company to commercial success.

Dr. Truesdale has over 20 years of experience in the life science and diagnostic sectors. He has held a variety of global leadership roles at Genetix plc, Danaher, and ThermoFisher Scientific. Most recently, he was CEO of Solentim Ltd., where he oversaw its operational and commercial scale-up which led to its acquisition by Advanced Instruments. Dr. Truesdale holds a BSc and PhD in biochemistry and molecular biology from the University of London.

Dr. Truesdale takes over from Thomas Van Elzakker, who has taken the company from a start-up to a scale-up, implementing the necessary structure to enable growth. FOx BIOSYSTEMS’ flagship product, WHITE FOx, uses an innovative fiber-optic SPR approach to characterize large biomolecules and particles and their kinetic interactions, directly in simple or complex matrices, such as whole blood or cell culture media.

Dr. Truesdale: “I am excited to join FOx BIOSYSTEMS at this stage of growth and am looking forward to using my skills to bring the company to commercial success. WHITE FOx has enormous potential in a range of life science applications, and I‘m confident it will make a very real difference to the field.”

“We are very happy to have Mark in this position. He is the ideal leader to bring this disruptive technology to a wider audience and ensure its further success.” - Katleen Vandersmissen, President of FOx BIOSYSTEMS’ Board of Directors

About FOx BIOSYSTEMS:

FOx BIOSYSTEMS is a Belgian company with a mission to revolutionize the life sciences and pharmacological research market with innovative real-time, label-free analysis products. The basis of their success is a novel fiber-optic-based SPR biosensor which enables users to generate high-quality, cost-effective biomolecular data fast, and over a wide range of applications.

For more information visit: www.foxbiosystems.com.

Join a Heran Fund

We are open to novel investments and are always planning the next funds and investment strategies. Leave your details below and our partners will be in touch.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Pitch your company

Submit your pitch below. We receive dozens of pitches each week and process these dilligently. We might not be able to get back to you immediately.

Max file size 10MB.
Uploading...
fileuploaded.jpg
Upload failed. Max size for files is 10 MB.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.